Trials / Recruiting
RecruitingNCT06648434
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zunsemetinib | Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water. |
| DRUG | mFOLFIRINOX | Includes oxaliplatin, irinotecan, leucovorin, and 5-FU. |
Timeline
- Start date
- 2025-05-15
- Primary completion
- 2027-06-30
- Completion
- 2030-05-31
- First posted
- 2024-10-18
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06648434. Inclusion in this directory is not an endorsement.